Drug Profile
Nalmefene nasal spray - Indivior
Alternative Names: Intranasal nalmefene - Opiant Pharmaceuticals; Nalmefene hydrochloride - Opiant Pharmaceuticals; Nalmefene hydrochloride nasal spray - Indivior; OPNT-003; OPVEE; OPVEE nasal sprayLatest Information Update: 18 Mar 2024
Price :
$50
*
At a glance
- Originator Opiant Pharmaceuticals
- Developer National Institute of Drug Abuse; Opiant Pharmaceuticals
- Class Anti-inflammatories; Opioid analgesics
- Mechanism of Action Opioid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Opioid-related disorders
Most Recent Events
- 11 Mar 2024 pharmacodynamics data from a phase I trial in healthy volunteers released by Indivior
- 22 May 2023 Registered for Opioid-related disorders (In adults, In adolescents) in USA (Intranasal) - First global approval
- 22 May 2023 Indivior intends to launch nalmefene nasal spray for Opioid-related disorders (In adolescents, In adults) in the fourth quarter of 2023